Loading...
SLDB logo

Solid Biosciences Inc.NasdaqGS:SLDB Stock Report

Market Cap US$722.6m
Share Price
US$7.19
US$17
57.7% undervalued intrinsic discount
1Y103.1%
7D8.6%
1D
Portfolio Value
​
View

Solid Biosciences Inc.

NasdaqGS:SLDB Stock Report

Market Cap: US$722.6m

Solid Biosciences (SLDB) Stock Overview

Develops therapies for neuromuscular and cardiac diseases in the United States. More details

SLDB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 93.9% below our estimate of its fair value

Revenue is forecast to grow 60.18% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the US market


SLDB Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Solid Biosciences Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Solid Biosciences
Historical stock prices
Current Share PriceUS$7.19
52 Week HighUS$8.87
52 Week LowUS$3.07
Beta2.47
1 Month Change0.84%
3 Month Change20.64%
1 Year Change103.11%
3 Year Change15.04%
5 Year Change-87.61%
Change since IPO-97.88%

Recent News & Updates

Seeking Alpha • Mar 12

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Summary Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. The company demonstrated 60% mean microdystrophin expression at Day 90 in its phase 1/2 INSPIRE DUCHENNE trial, with safety confirmed in 40 patients. A $240 million private placement in March 2026 extends the cash runway, supporting key milestones through 2027. Upcoming catalysts include phase 3 IMPACT DUCHENNE first dosing in Q1 2026 and a potential FDA Accelerated Approval update by mid-2026. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Mar 12

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Summary Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. The company demonstrated 60% mean microdystrophin expression at Day 90 in its phase 1/2 INSPIRE DUCHENNE trial, with safety confirmed in 40 patients. A $240 million private placement in March 2026 extends the cash runway, supporting key milestones through 2027. Upcoming catalysts include phase 3 IMPACT DUCHENNE first dosing in Q1 2026 and a potential FDA Accelerated Approval update by mid-2026. Read the full article on Seeking Alpha
Analysis Article • Oct 23

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 09

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 08

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Summary Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects. Despite risks, Solid's strong financial position and potential market disruption with SGT-003 make it a Buy, assuming continued safety and favorable Sarepta developments. Read the full article on Seeking Alpha
Seeking Alpha • Jan 21

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Summary Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025. SGT-501 is another gene therapy product candidate with an expected IND filing in the 1st half of 2025 for the treatment of patients with RYR2-mediated Catecholaminergic Polymorphic Ventricular Tachycardia. Read the full article on Seeking Alpha
Analysis Article • Nov 16

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 26

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Solid...
Seeking Alpha • Apr 10

Buy Solid Biosciences: Unpacking Its Main Value Driver

Summary Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation. SLDB's valuation appears undervalued relative to its peers, which is why I ultimately lean bullish post-PIPE investment. Read the full article on Seeking Alpha
Seeking Alpha • Jan 17

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression. An IND filing to begin a phase 1 study using SGT-501 for the treatment of patients with catecholaminergic polymorphic ventricular tachycardia is expected by Q1 of 2025. Read the full article on Seeking Alpha
Seeking Alpha • Sep 30

Solid Biosciences to acquire gene therapy company AavantiBio

Life sciences company Solid Biosciences (NASDAQ:SLDB) will acquire the gene therapy company AavantiBio. The combined entity aims to advance a portfolio of neuromuscular and cardiac programs. The merger is subject to an approval by the shareholders of Solid. Post the transaction, the current CEO of AavantiBio, Bo Cumbo, will assume the role of president and CEO of Solid Biosciences. In support of the acquisition, SLDB has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $75M private placement. The private placement is expected to close concurrently with the closing of the merger in Q4. The combined entity is expected to have total cash and investments of ~$215M post the closing of the merger. SLDB shares were trading +17.47% pre-market. Source: Press Release
Analysis Article • Apr 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...
Analysis Article • Apr 28

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...
Analysis Article • Mar 17

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

SLDBUS BiotechsUS Market
7D8.6%1.2%1.6%
1Y103.1%35.1%28.2%

Return vs Industry: SLDB exceeded the US Biotechs industry which returned 35.1% over the past year.

Return vs Market: SLDB exceeded the US Market which returned 28.2% over the past year.

Price Volatility

Is SLDB's price volatile compared to industry and market?
SLDB volatility
SLDB Average Weekly Movement12.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: SLDB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SLDB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013121Bo Cumbowww.solidbio.com

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.

Solid Biosciences Inc. Fundamentals Summary

How do Solid Biosciences's earnings and revenue compare to its market cap?
SLDB fundamental statistics
Market capUS$722.62m
Earnings (TTM)-US$191.78m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.7x
P/E Ratio

Is SLDB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLDB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$191.78m
Earnings-US$191.78m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.95
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SLDB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 13:27
End of Day Share Price 2026/06/01 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Solid Biosciences Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangBTIG
Kristen KluskaCantor Fitzgerald & Co.
Charles DuncanCantor Fitzgerald & Co.